Biosimilars Market Access in the EU and USA
This biosimilars course addresses the available options for market access in the US and EU, including negotiating with the originator.
-
This biosimilars course addresses the available options for market access in the US and EU, including negotiating with the originator.52.5320414 13.3441316
| Wann |
19.05.2020 von 09:00 bis 17:00 |
|---|---|
| Veranstaltungsort | Mercure Hotel MOA Berlin |
| Stadt | Berlin |
| Kontaktname | Dr. Henriette Wolf-Klein |
| Kontakttelefon | +49 6221 500-680 |
| Zielgruppe |
This course is intended for managing directors, market access managers, legal and IP departments involved in placing a biosimilar product on EU or US markets. |
| Termin übernehmen |
vCal
iCal
|
Seminar target:
This course will prepare you for a biosimilar market entry in the EU or USA. It will give you a deeper understanding of the available options for negotiating, licencing and challenging patents, and how to promote your market entry with a distinctive pre-launch communication and appropriate tenders.
Topics:
- Licencing or challenging patents in the USA
- Negotiating settlement agreements
- First to market requirements for the main EU markets
- Negotiating exclusivity rights for the EU markets
Weitere Informationen über diesen Termin…
FORUM Institut für Management GmbH
Programm
2005230.pdf
—
PDF document,
285 kB (292,319 bytes)
